High levels of blood circulating immune checkpoint molecules in children with new-onset type 1 diabetes are associated with the risk of developing an additional autoimmune disease
Tóm tắt
We assessed the levels of blood circulating immune checkpoint molecules (ICMs) at diagnosis of type 1 diabetes, and determined their association with the risk of developing an additional autoimmune disorder over time. Children with new-onset type 1 diabetes (n = 143), without biological and/or clinical signs of additional autoimmune disorders, and healthy children (n = 75) were enrolled, and blood circulating levels of 14 ICMs were measured. The children with type 1 diabetes were divided into two groups on the basis of the development of an additional autoimmune disease in the 5 years after diabetes onset. Differences in soluble ICM levels between the groups were assessed, and a Cox regression analysis was used to evaluate their association with the risk of development of an additional autoimmune disease over time. To validate the data, circulating ICMs were measured in an independent cohort of 60 children with new-onset type 1 diabetes stratified into two groups. We found that the levels of circulating ICMs were significantly higher in children with new-onset diabetes compared with healthy children. Further, we observed that children with type 1 diabetes who developed a second autoimmune disease over time (T1D-AAD+ children) had higher levels of soluble ICMs than children with type 1 diabetes who did not (T1D-AAD− children). Cox regression models revealed that high circulating levels of CD137/4-1BB and PD-1 molecules at diabetes diagnosis were associated with the risk of developing an additional autoimmune disease in both type 1 diabetes cohorts. Our findings suggest that soluble CD137/4-1BB and PD-1 molecules may be used as prognostic biomarkers in children with type 1 diabetes, and may pave the way for novel immunological screening at diabetes onset, allowing early identification of children at higher risk of developing other autoimmune conditions over time.
Tài liệu tham khảo
Norris JM, Johnson RK, Stene LC (2020) Type 1 diabetes – early life origins and changing epidemiology. Lancet Diabetes Endocrinol 8(3):226–238. https://doi.org/10.1016/s2213-8587(19)30412-7
Barker JM (2006) Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 91(4):1210–1217. https://doi.org/10.1210/jc.2005-1679
Triolo TM, Armstrong TK, McFann K et al (2011) Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 34(5):1211–1213. https://doi.org/10.2337/dc10-1756
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239
Kong Y, Wang Y, Wu X et al (2020) Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Targeted Ther 5(1):192. https://doi.org/10.1038/s41392-020-00308-2
Gu D, Ao X, Yang Y, Chen Z, Xu X (2018) Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer 6(1):132. https://doi.org/10.1186/s40425-018-0449-0
Itoh A, Ortiz L, Kachapati K et al (2019) Soluble CD137 ameliorates acute type 1 diabetes by inducing T cell anergy. Front Immunol 10:2566. https://doi.org/10.3389/fimmu.2019.02566
Gerold KD, Zheng P, Rainbow DB, Zernecke A, Wicker LS, Kissler S (2011) The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 60(7):1955–1963. https://doi.org/10.2337/db11-0130
Makimattila S, Harjutsalo V, Forsblom C, Groop PH, FinnDiane Study Group (2020) Every fifth individual with type 1 diabetes suffers from an additional autoimmune disease: a Finnish nationwide study. Diabetes Care 43(5):1041–1047. https://doi.org/10.2337/dc19-2429
Mayer-Davis EJ, Kahkoska AR, Jefferies C et al (2018) ISPAD clinical practice consensus guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 19(Suppl 27):7–19. https://doi.org/10.1111/pedi.12773
Terrazzano G, Bruzzaniti S, Rubino V et al (2020) T1D progression is associated with loss of CD3+CD56+ regulatory T cells that control CD8+ T cell effector functions. Nature Metab 2(2):142–152. https://doi.org/10.1038/s42255-020-0173-1
Hanley P, Lord K, Bauer AJ (2016) Thyroid disorders in children and adolescents: a review. JAMA Pediatr 170(10):1008–1019. https://doi.org/10.1001/jamapediatrics.2016.0486
Husby S, Koletzko S, Korponay-Szabo IR et al (2012) European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 54(1):136–160. https://doi.org/10.1097/MPG.0b013e31821a23d0
Royston P, Ambler G, Sauerbrei W (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 28(5):964–974. https://doi.org/10.1093/ije/28.5.964
Ambler G, Royston P (2001) Fractional polynomial model selection procedures: investigation of type i error rate. J Stat Comput Simul 69(1):89–108. https://doi.org/10.1080/00949650108812083
Dai S, Jia R, Zhang X, Fang Q, Huang L (2014) The PD-1/PD-ls pathway and autoimmune diseases. Cell Immunol 290(1):72–79. https://doi.org/10.1016/j.cellimm.2014.05.006